About this document
Selective Inhibition of CDK9 in Triple Negative Breast Cancer by Ran Lin is a document available to read on EtoBox.
The study investigates the efficacy of a novel selective CDK9 inhibitor, CDDD11-8, in treating triple-negative breast cancer (TNBC), which is characterized by its aggressive nature and lack of targeted therapies. CDDD11-8 demonstrated significant anti-proliferative effects in various TNBC models, inducing cell cycle arrest and apoptosis while effectively inhibiting CDK9 activity and down-regulating oncogenes like MYC and MCL1. The findings suggest that CDK9 is a promising therapeutic target in TNBC, with CD
- Author
- Ran Lin
- Language
- EN